ANTX - AN2 Therapeutics, Inc.
4.8
0.460 9.583%
Share volume: 618,572
Last Updated: 04-27-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$4.34
0.46
0.11%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-14-2024 | 08-13-2024 | 11-13-2024 | 03-25-2025 | 05-13-2025 | 11-12-2025 | 03-17-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 18.296 M | 15.880 M | 11.771 M | 8.607 M | 11.537 M | 10.040 M | 9.316 M | |
| Selling general and admin | 3.641 M | 3.731 M | 3.484 M | 3.210 M | 3.847 M | 3.040 M | 2.437 M | |
| Research and development | 14.655 M | 12.149 M | 8.287 M | 5.397 M | 7.690 M | 7.000 M | 6.879 M | |
| Total expenses | 18.296 M | 15.880 M | 14.014 M | 8.598 M | 11.537 M | 10.040 M | 9.316 M | |
| -13.21% | -11.75% | -38.65% | 34.18% | -12.98% | -7.21% | |||
| Operating income | -18.296 M | -15.880 M | -14.014 M | -8.598 M | -11.537 M | -10.040 M | -9.316 M | |
| Ebit | -16.617 M | -15.880 M | -12.747 M | -8.598 M | -11.537 M | -10.040 M | -9.315 M | |
| Pretax income | -16.617 M | -15.880 M | -12.747 M | -6.077 M | -10.649 M | -9.353 M | -8.710 M | |
| -4.44% | -19.73% | -52.33% | 75.23% | -12.17% | -6.87% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -16.617 M | -14.435 M | -12.747 M | -7.522 M | -10.649 M | -9.353 M | -8.710 M | |
| 13.13% | 11.69% | 40.99% | -41.57% | 12.17% | 6.87% |